Literature DB >> 33648449

The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.

Ming Zeng1, Jian Zhou1, Lifang Wen2, Yanshan Zhu2, Yingquan Luo3, Wanchun Wang4.   

Abstract

BACKGROUND: A number of studies have linked positive Ki-67 expression with the prognosis of osteosarcoma (OS) patients. However, the results have been conflicting. To address this controversy, we conducted an analysis using a meta-analysis and a TCGA dataset to estimate the value of Ki-67 expression in the prognosis of OS.
METHODS: A comprehensive search for relevant papers was conducted using NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane Library, and CNKI regardless of the publication year. The associations between Ki-67 expression and the clinical features and main prognostic outcomes of OS were measured. The TCGA dataset was also analyzed. The pooled odds ratio (OR) and its 95% confidential intervals (CIs) were utilized for statistical analysis.
RESULTS: Overall, a total of 12 studies with 500 cases were included, and the results indicated that the expression of Ki-67 was significantly associated with Enneking stage (OR = 6.88, 95% CI: 2.92-16.22, p < 0.05), distant metastasis (OR = 3.04, 95% CI: 1.51-6.12, p < 0.05) and overall survival (OR = 8.82, 95% CI: 4.68-16.65, p < 0.05) in OS patients. Additionally, we observed no significant heterogeneity among all retrieved studies. Associations between Ki-67 expression and overall survival and disease-free survival of sarcoma were confirmed using the TCGA and Kaplan-Meier plotter datasets.
CONCLUSION: The present study strongly suggests that positive Ki-67 expression was associated with Enneking stage, distant metastasis, and overall survival of OS, and it may be used as a potential biomarker to predict prognosis and guide clinical therapy for OS.

Entities:  

Keywords:  Clinicopathological features; Ki-67; Meta-analysis; Osteosarcoma; Prognosis; TCGA dataset

Mesh:

Substances:

Year:  2021        PMID: 33648449      PMCID: PMC7923819          DOI: 10.1186/s12885-021-07880-y

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  42 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 2.  Osteosarcoma, Chondrosarcoma, and Chordoma.

Authors:  Jeremy S Whelan; Lara E Davis
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

3.  Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients.

Authors:  Ayse Durnali; Necati Alkis; Sengul Cangur; Fisun Ardic Yukruk; Ali Inal; Saadet Tokluoglu; Mehmet Metin Seker; Oznur Bal; Tulay Akman; Mevlude Inanc; Abdurrahman Isikdogan; Ayse Demirci; Kaan Helvaci; Berna Oksuzoglu
Journal:  Med Oncol       Date:  2013-06-09       Impact factor: 3.064

Review 4.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 5.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

6.  The prognostic role of CD133 expression in patients with osteosarcoma.

Authors:  Nuo Xu; Yijun Kang; Wanchun Wang; Jian Zhou
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

7.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

Review 8.  Osteosarcoma.

Authors:  Drew D Moore; Hue H Luu
Journal:  Cancer Treat Res       Date:  2014

9.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

10.  Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.

Authors:  Hongzeng Wu; Jinming Zhang; Ruoheng Dai; Jianfa Xu; Helin Feng
Journal:  J Orthop Surg Res       Date:  2019-09-04       Impact factor: 2.359

View more
  5 in total

1.  Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Naohiro Oka; Ryosuke Kakinoki; Masao Akagi
Journal:  Eur J Histochem       Date:  2022-06-23       Impact factor: 1.966

2.  Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas.

Authors:  Ştefan Adrian Niculescu; Dan Cristian Grecu; Cristiana Eugenia Simionescu; Elena Carmen Niculescu; Mioara Desdemona Stepan; Alex Emilian Stepan
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

Review 3.  Emerging Applications of Deep Learning in Bone Tumors: Current Advances and Challenges.

Authors:  Xiaowen Zhou; Hua Wang; Chengyao Feng; Ruilin Xu; Yu He; Lan Li; Chao Tu
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

4.  Association between malnutrition and leucopenia in patients with osteosarcoma.

Authors:  Haixiao Wu; Shu Li; Yile Lin; Jun Wang; Vladimir P Chekhonin; Karl Peltzer; Vladimir P Baklaushev; Kirellos Said Abbas; Jin Zhang; Huiyang Li; Chao Zhang
Journal:  Front Nutr       Date:  2022-07-28

Review 5.  The roles of glycolysis in osteosarcoma.

Authors:  Zuxi Feng; Yanghuan Ou; Liang Hao
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.